Use: Labeled indications
- INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of BACTRIM (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, BACTRIM (sulfamethoxazole…
Full indications and usage US FDA label
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of BACTRIM (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, BACTRIM (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris.
It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents.
To date, there are limited data on the safety of repeated use of BACTRIM in pediatric patients under two years of age. BACTRIM is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that BACTRIM could offer some advantage over the use of a single antimicrobial agent.
Shigellosis For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis jirovecii Pneumonia For the treatment of documented Pneumocystis jirovecii pneumonia and for prophylaxis against P. jirovecii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing P. jirovecii pneumonia.
Traveler's Diarrhea in Adults For the treatment of traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli.
Contraindications
- Hypersensitivity to trimethoprim or sulfonamides
- Drug-induced immune thrombocytopenia with either component
- Megaloblastic anemia from folate deficiency
- Infants under 2 months
- Marked hepatic damage
- Severe renal insufficiency when renal function cannot be monitored
- Concomitant dofetilide
Contraindications (US label) US FDA label
CONTRAINDICATIONS BACTRIM is contraindicated in the following situations: a known hypersensitivity to trimethoprim or sulfonamides history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides documented megaloblastic anemia due to folate deficiency pediatric patients less than 2 months of age marked hepatic damage severe renal insufficiency when renal function status cannot be monitored concomitant administration with dofetilide (see PRECAUTIONS).
Dosing: Adult
- Urinary tract infection, shigellosis (adults): 800/160 mg (1 DS tablet) every 12 hours; 10 to 14 days (UTI) or 5 days (shigellosis)
- Pneumocystis pneumonia treatment: Sulfamethoxazole 75 to 100 mg/kg and trimethoprim 15 to 20 mg/kg per day in divided doses every 6 hours for 14 to 21 days
- Pneumocystis prophylaxis (adults): 800/160 mg (1 DS tablet) daily
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION BACTRIM is contraindicated in pediatric patients less than 2 months of age. Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children Adults: The usual adult dosage in the treatment of urinary tract infections is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 10 to 14 days.
An identical daily dosage is used for 5 days in the treatment of shigellosis. Children: The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.
The following table is a guideline for the attainment of this dosage: Children 2 months of age or older: Weight Dose–every 12 hours lb kg Tablets 22 10 – 44 20 1 66 30 1½ 88 40 2 or 1 DS tablet For Patients with Impaired Renal Function When renal function is impaired, a reduced dosage should be employed using the following table: Creatinine Clearance (mL/min) Recommended Dosage Regimen Above 30 Usual standard regimen 15–30 ½ the usual regimen Below 15 Use not recommended Acute Exacerbations of Chronic Bronchitis in Adults The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 14 days. Pneumocystis jirovecii Pneumonia Treatment Adults and Children: The recommended dosage for treatment of patients with documented Pneumocystis jirovecii pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. 12 The following table is a guideline for the upper limit of this dosage: Weight Dose–every 6 hours lb kg Tablets 18 8 – 35 16 1 53 24 1½ 70 32 2 or 1 DS tablet 88 40 2½ 106 48 3 or 1½ DS tablets 141 64 4 or 2 DS tablets 176 80 5 or 2½ DS tablets For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.
Prophylaxis Adults: The recommended dosage for prophylaxis in adults is 1 BACTRIM DS (double strength) tablet daily. 13 Children: For children, the recommended dose is 750 mg/m 2 /day sulfamethoxazole with 150 mg/m 2 /day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim. 14 The following table is a guideline for the attainment of this dosage in children: Body Surface Area Dose–every 12 hours (m 2) Tablets 0.26 – 0.53 ½ 1.06 1 Traveler’s Diarrhea in Adults For the treatment of traveler’s diarrhea, the usual adult dosage is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 5 days.
Dosing: Altered kidney function
Both components are cleared by the kidneys. The US label uses the usual regimen above creatinine clearance (CrCl) 30 mL/min, half the usual regimen at 15–30, and does not recommend use below 15. Trimethoprim can cause hyperkalemia (worse with ACE inhibitors, ARBs or kidney impairment) and raises serum creatinine by blocking tubular secretion; crystalluria and interstitial nephritis also occur.
Kidney function measure: Label uses CrCl (mL/min): >30, 15–30, <15.
Show full dosing details
- CrCl ≥60 mL/min
- Usual regimen (label: CrCl above 30). Keep the patient well hydrated.
- CrCl 30–59 mL/min
- Usual regimen at CrCl above 30 (label). Hyperkalemia risk rises in kidney impairment: check potassium, especially with ACE inhibitors, ARBs or spironolactone.
- CrCl 15–29 mL/min
- Half the usual regimen at CrCl 15–30 (label). Monitor potassium and creatinine.
- CrCl <15 mL/min (not on dialysis)
- Use not recommended at CrCl below 15 mL/min (label table).
- Hemodialysis (intermittent)
- Label: not recommended below CrCl 15 and gives no dialysis dose; hemodialysis is only moderately effective at removing both components. Use in dialysis (e.g., Pneumocystis prophylaxis) is a specialist decision.
- Peritoneal dialysis
- Not recommended below CrCl 15 (label); peritoneal dialysis does not remove it. Specialist decision.
- CRRT
- Li 2020 (CRRT review, Table 3): trimethoprim 10 mg/kg/day divided every 12 hours may be a reasonable starting dose in CVVH or CVVHD (ultrafiltration or dialysate 1–6 L/h); no dose recommended for CVVHDF because of variable sulfamethoxazole clearance.
- Dialyzable? Moderately by hemodialysis; peritoneal dialysis is not effective (label 10). Both removed by CVVHDF (Li 2020).
- Monitoring Potassium (hyperkalemia), creatinine (a rise may reflect blocked tubular secretion of creatinine as well as injury), complete blood count, urinalysis for crystalluria; fluid intake. Sodium (hyponatremia).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual weight-based dose (label).
- eGFR 30–59
- Usual dose at CrCl above 30 (label kidney table is not age-limited). Check potassium.
- eGFR 15–29
- Half the usual regimen at CrCl 15–30 (label).
- eGFR <15 (not on dialysis)
- Not recommended below CrCl 15 (label).
- Hemodialysis (intermittent)
- Not recommended (label); specialist decision.
- Peritoneal dialysis
- Not recommended (label); specialist decision.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Patients with Impaired Renal Function When renal function is impaired, a reduced dosage should be employed using the following table: Creatinine Clearance (mL/min) Recommended Dosage Regimen Above 30 Usual standard regimen 15–30 ½ the usual regimen Below 15 Use not recommended Acute Exacerbations of Chronic Bronchitis in Adults The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 14 days. Pneumocystis jirovecii Pneumonia Treatment Adults and Children: The recommended dosage for treatment of patients with documented Pneumocystis jirovecii pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. 12 The following table is a guideline for the upper limit of this dosage: Weight Dose–every 6 hours lb kg Tablets 18 8 – 35 16 1 53 24 1½ 70 32 2 or 1 DS tablet 88 40 2½ 106 48 3 or 1½ DS tablets 141 64 4 or 2 DS tablets 176 80 5 or 2½ DS tablets For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.
Prophylaxis Adults: The recommended dosage for prophylaxis in adults is 1 BACTRIM DS (double strength) tablet daily. 13 Children: For children, the recommended dose is 750 mg/m 2 /day sulfamethoxazole with 150 mg/m 2 /day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim. 14 The following table is a guideline for the attainment of this dosage in children: Body Surface Area Dose–every 12 hours (m 2) Tablets 0.26 – 0.53 ½ 1.06 1 Traveler’s Diarrhea in Adults For the treatment of traveler’s diarrhea, the usual adult dosage is 1 BACTRIM DS (double strength) tablet or 2 BACTRIM tablets every 12 hours for 5 days.
Dosing: Pediatric
- Approved ages
- 2 months and older; contraindicated under 2 months (label).
- Usual dose
- UTI and otitis media: sulfamethoxazole 40 mg/kg and trimethoprim 8 mg/kg per 24 hours in 2 doses. Pneumocystis treatment: sulfamethoxazole 75 to 100 mg/kg and trimethoprim 15 to 20 mg/kg per 24 hours in 4 doses. Pneumocystis prophylaxis: 750/150 mg/m2/day in 2 doses on 3 consecutive days per week (label).
- Maximum dose
- Prophylaxis: no more than sulfamethoxazole 1,600 mg and trimethoprim 320 mg per day (label).
- Neonates
- Contraindicated under 2 months of age (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use BACTRIM is contraindicated for infants younger than 2 months of age (see INDICATIONS AND USAGE and CONTRAINDICATIONS sections).
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs.
Severe skin reactions, generalized bone marrow suppression (see WARNINGS and ADVERSE REACTIONS sections), a specific decrease in platelets (with or without purpura), and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.
Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see DOSAGE AND ADMINISTRATION section).
The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients.
Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. BACTRIM Tablets contain 1.8 mg sodium (0.08 mEq) of sodium per tablet. BACTRIM DS Tablets contain 3.6 mg (0.16 mEq) of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects.
The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects (see CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics).
Dosage forms
Philippines
- Tablet: 400 mg/80 mg, 480 mg, 800 mg/160 mg, 960 mg
- Suspension: 200 mg/40 mg per 5 mL, 240 mg per 5 mL, 240 mg/5 mL, 400 mg/80 mg per 5 mL, 480 mg per 5 mL
- Powder for suspension: 240 mg/5 mL, 480 mg/5 mL
- Capsule: 80 mg, 400 mg/80 mg, 480 mg
- Oral suspension: 400 mg/80 mg per 5 mL
- Per tablet: 400 mg/80 mg, 800 mg/160 mg
- Solution for intravenous infusion: 480 mg/5 mL
- Forte suspension: 400 mg/80 mg per 5 mL
- Solution for iv infusion: 400 mg/80 mg per 5 mL
Registered products in the Philippines
88 products registered with the Food and Drug Administration (FDA) Philippines list Sulfamethoxazole + Trimethoprim as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products88
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlcotriCo-trimoxazole | 240 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Bulacan | Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DR-XY22710 | Mar 12, 2032 | |
Bactille TSCotrimoxazole | 400 mg / 80 mg per 5mL SuspensionBoston Round Amber Glass Bottle x 75 mL Box of 1’s | Rx | Hizon Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY17489 | Nov 6, 2028 | |
BactizoleCotrimoxazole | 240 mg per 5mL SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | Reta Drug | DRP-083-09 | Apr 8, 2029 | |
BactrexCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4549 | Jul 26, 2028 | |
Betrim ForteCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack (Box of 14's) | Rx | Milan Laboratories Private LimitedIndia | Khriz Pharma Trading Inc. | DR-XY49508 | Sep 10, 2030 | |
BruprimCotrimoxazole | 480 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-4608 | Aug 27, 2028 | |
Bruprim DSCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-5764 | Apr 5, 2028 | |
CombizoleCotrimoxazole | 960 mg TabletAlu/Light Violet PVC Blister Pack x 10's (Box of 100's and 500's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-8391 | Oct 12, 2031 | |
CotribaseCotrimoxazole | 200 mg/40 mg per 5 mL Suspension60 mL Amber Glass Bottle | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corp. | DR-XY17315-B | Sep 12, 2027 | |
Cotribase ForteCotrimoxazole | 800 mg/160 mg TabletClear PVC/Aluminum Strip 10 x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corp. | DR-XY22020-B | Sep 12, 2027 | |
CotridCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals Inc. | DRP-5388-02 | Aug 28, 2029 | |
CotrigenCotrimoxazole | 400 mg/80 mg per 5 mL Oral SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC.Trader: ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4953-01 | Nov 26, 2028 | |
CotrigenCotrimoxazole | 960 mg TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC. | DRP-4549-01 | Jul 23, 2028 | |
CotrilifeCotrimoxazole | 240 mg/5 mL Powder for SuspensionAmber glass bottle x 60 mL-net content with blue aluminum cap (Box of 1's) | Rx | Nucare Labs LLPIndia | Biophil Medical Equipment and Supplies Trading | DRP-17669 | Feb 13, 2031 | |
CotrilifeCotrimoxazole | 480mg/5mL Powder for Suspension (Vanilla Flavor) | Rx | Galen Pharmaceuticals LimitedIndia | Biophil Medical Equipment and Supplies Trading | DRP-17707 | Feb 20, 2031 | |
CotrimaxolCotrimoxazole (Butterscotch Flavor) | 200 mg/40 mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-5447 | Dec 17, 2029 | |
CotrimaxolCotrimoxazole | 400mg/80mg TabletAlu/Clear PVC Blister pack x 10's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5255 | Jul 28, 2027 | |
CotrimaxolCotrimoxazole | 800 mg/160 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmakers Laboratories, Inc.E & E Industrial Complex Brgy. San Antonio San Pedro Laguna | — | DRP-5256 | Nov 19, 2036 | |
CotripelCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-4549-05 | Jul 26, 2028 | |
CotrivaCotrimoxazole | 480 mg/5 mL Solution for Intravenous Infusion5 mL amber glass ampoule with plastic tray (Box of 5's) | Rx | Swiss Parenterals Ltd.India | Biocare Lifesciences Inc. | DRP-18319 | Jul 21, 2032 | |
CozoleCotrimoxazole | 240mg per 5mL SuspensionAmber Bottle x 60mL Box of 1's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY22753-B | Sep 4, 2027 | |
CozoleCotrimoxazole | 400 mg/80 mg per TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Malolos Bulacan | Trader: Metz Pharmaceuticals, Inc. | DR-XY17719-B | Oct 15, 2037 | |
CozoleCotrimoxazole | 800 mg/160 mg per Tablet (see reverse for formulation)Alu-PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY21455-B | Oct 15, 2027 | |
CozoleCotrimoxazole | 960 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY47006 | Aug 27, 2030 | |
DiazoleCotrimoxazole | 800 mg/160 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-250 | Feb 5, 2028 | |
Drilozole DSCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: ldril Pharmaceuticals, Inc. | DR-XY23824 | Feb 4, 2028 | |
Drilozole DSCotrimoxazole | 800 mg/160 mg TabletAlu / PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-16079 | Feb 4, 2028 | |
EmbatrimCotrimoxazole | 480 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY29009 | Oct 3, 2028 | |
EmbatrimCotrimoxazole | 480 mg TabletAlu / Alu Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-16774 | Oct 3, 2028 | |
Embatrim ForteCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-458 | Oct 15, 2028 | |
GlobaxolCotrimoxazolë | 400 mg/80 mg per 5 mL Forte SuspensionBoston Round Amber Glass Bottle with 10 mL Plastic Measuring Cup x 60 mL (Box of l’s) | Rx | Hizon Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY31336 | Aug 5, 2027 | |
HealthcareCotrimoxazole | 200 mg/40 mg per 5 mL SuspensionAmber Bottle x 60 mL | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY39829 (For Export Only) | Jun 27, 2030 | |
JenetrolCotrimoxazole | 960mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-082-03 | Feb 13, 2029 | |
JestrimCotrimoxazole | 200 mg/40 mg per 5 mL SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DR-XY15068 | Feb 1, 2030 | |
KathrexCotrimoxazole | 240 mg per 5mL SuspensionBoston Round Amber Glass Bottle x 60mL Box of 1's | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-083 | Apr 8, 2029 | |
KathrexCotrimoxazole | 400 mg/80 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-1620 | Feb 25, 2030 | |
KathrexCotrimoxazole | 480 mg per 5 mL SuspensionAmber Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-080 | Sep 17, 2030 | |
KathrexCotrimoxazole | 960 mg TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-082 | Feb 13, 2029 | |
MoxatrimCotrimoxazole (Butterscotch Flavor) | 200mg/40mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Drugmaker’s Laboratories Inc.Philippines | Phil. Pharmawealth Inc. | DRP-5447-01 | Dec 17, 2029 | |
NoneCotrimoxazole | 240 mg per 5 mL SuspensionAmber Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY44599 | May 25, 2030 | |
NoneCotrimoxazole | 240 mg per 5 mL SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-083-10 | Apr 8, 2029 | |
NoneCotrimoxazole | 400 mg/80 mg per 5 mL Oral SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | 999 SETH PHARMACEUTICAL INC.Trader: ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4953-02 | Nov 26, 2028 | |
NoneCotrimoxazole | 400/80 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DR-XY16088 | May 21, 2028 | |
NoneCotrimoxazole | 480 mg TabletAlu / Alu Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-16774-01 | Oct 3, 2028 | |
NoneCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Brawn Laboratories LimitedIndia | PharmaVital Corp.Importer: Ambica International Corporation | DRP-5764-02 | Apr 5, 2028 | |
NoneCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-458-04 | Oct 15, 2028 | |
NoneCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's( | Rx | Brawn Laboratories Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-5764-01 | Apr 5, 2028 | |
PrimecotrixCotrimoxazole | 200 mg/40 mg per 5 mL Suspension | Rx | Lloyd Laboratories, Inc. | Trader: Primera Pharma, Corp. | DR-XY20496-B | Nov 28, 2026 | |
ProcorCotrimoxazole | 200 mg/40 mg per 5 mL SuspensionAmber Glass Bottle x 75 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Heltker A.G. Corporation | DR-XY20382-B | Dec 15, 2027 | |
RegizoleCotrimoxazole | 240 mg per 5 mL SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-083-01 | Apr 8, 2029 | |
RegizoleCotrimoxazole | 400mg/80mg per 5mL SuspensionAmber Bottle x 60mL (Box of 1's); Amber Bottle x 60mL (For DOH Project Only) | Rx | New Myrex Laboratories, Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-080-01 | Aug 6, 2031 | |
RegizoleCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-082-02 | Feb 13, 2029 | |
RenatrimCotrimoxazole | 240 mg per 5 mL Suspension (see reverse for formulation)Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-10016 | Feb 8, 2028 | |
SeptrolCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | Seammed Pharma | DRP-082-04 | Feb 13, 2029 | |
Septrol-MCotrimoxazole | 240mg per 5mL SuspensionBoston Round Amber Glass Bottle x 60mL Box of 1's | Rx | New Myrex Laboratories, Inc.Philippines | Seammed Pharma | DRP-083-04 | Apr 8, 2029 | |
SynermedCotrimoxazole | 960 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY47008 | Aug 27, 2030 | |
TriaxoleCotrimoxazole | 960 mg TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | 999 SETH PHARMACEUTICAL INC. | DRP-4549-02 | Jul 26, 2028 | |
TriforamCotrimoxazole | 240 mg/5 mL Suspension60 mL Amber Glass Bottle | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: Foramen Products Corporation | DR-XY24373 | Jul 23, 2028 | |
TriforamCotrimoxazole | 960 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Foramen Products Corporation | DRP-9063 | Aug 27, 2030 | |
TrimexzoleCo-trimoxazole | 400 mg/ 80 mg per 5 mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY44038 | Jan 20, 2030 | |
TrimezoleCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Vitalife Pharma and Medical Supply Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-5388-03 | Aug 28, 2029 | |
TrimostatCotrimoxazole | 240 mg /5 mL Powder for Suspension60 mL Amber-Colored Plastic Bottle (Box of 1’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-16769 | Jun 11, 2028 | |
TrimostatCotrimoxazole | 240 mg/5 mL Powder for Suspension60 mL Amber-Colored Plastic Bottle (Box of 1’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY34643 | Jun 11, 2028 | |
TrimoxedCotrimoxazole | 960 mg TabletAlu/Light Violet PVC Blister Pack x 10's (Box of 100's and 500's) | Rx | Sapphire Lifesciences Pvt. LtdIndia | 777 Red Pharma IncImporter: Nelpa Lifesciences, Inc. | DRP-8391-01 | Oct 12, 2031 | |
TrimozolCo-Trimoxazole | 480 mg/5 mL Solution for Intravenous Infusion5 mL Type I glass ampoule (Box of 10’s) | Rx | Swiss Pharmaceutical Co., Ltd (Xinshi Plant)Taiwan | Global Pharmatrade | DR-XY47239 | Apr 22, 2031 | |
TriphimoxCotrimoxazole | 200 mg/40 mg per 5 mL Suspension60 mL Amber Glass Bottle | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY14111 | Jun 30, 2028 | |
TriphimoxCotrimoxazole | 400 mg/80 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY19183-B | Mar 1, 2027 | |
TriphimoxCotrimoxazole | 480 mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY16063-B | Jan 3, 2028 | |
TriphimoxCotrimoxazole | 960 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY47010 | Aug 27, 2030 | |
TrisulcomCotrimoxazole | 200 mg/40 mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY19093 | Sep 23, 2027 | |
TrisulcomCotrimoxazole | 400 mg/80 mg CapsuleAmber Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY19097 | Feb 17, 2028 | |
Trisulcom ForteCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-2406 | May 18, 2028 | |
Trisulcom ForteCotrimoxazole | 960 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-9062 | Aug 27, 2030 | |
TrizoleCotrimoxazole | 400 mg / 80 mg per 5 mL SuspensionAmber bottle x 30 mL and 60 mL Box of 1's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY185 | Mar 25, 2029 | |
TrymerinCotrimoxazole | 240 mg per 5 mL SuspensionBoston Round Amber Glass Bottle x 60 mL Box of 1's | Rx | New Myrex Laboratories, Inc.Philippines | Lumar Pharmaceutical Laboratory Inc. | DRP-083-03 | Apr 8, 2029 | |
TrymerinCotrimoxazole | 400 mg/80 mg per 5 mL SuspensionAmber Bottle x 60 mL | Rx | New Myrex Laboratories, Inc.Philippines | Lumar Pharmaceutical Laboratory, Inc. | DRP-080-03 | Jul 31, 2031 | |
TrymerinCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | Lumar Pharmaceutical Laboratory, Inc. | DRP-082-01 | Feb 13, 2029 | |
UnbrandedCotrimoxazole | 480 mg CapsuleALU/ Clear PvC Blister Pack X 10's (Box of 100's) | Rx | Eurasia Research Pharma CorporationPhilippines | — | DR-XY45250 | Apr 11, 2031 | |
UnbrandedCotrimoxazole | 800mg/160mg Tablet | Rx | — | TGP Pharma Inc. | DRP-5256-01 | Nov 19, 2026 | |
UrobacCotrimoxazole | 960 mg TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4549-03 | Jul 26, 2028 | |
XanazoleCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | Rx | Marnets Pharma CorporationPhilippines | — | DRP-438 | Aug 11, 2027 | |
XolfatrimCotrimoxazole | 400 mg/80 mg per 5 mL Oral SuspensionBoston Round Amber Glass Bottle x 60 mL Box of 1's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4953 | Nov 26, 2028 | |
XolfatrimCotrimoxazole | 960 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-4549-04 | Jul 26, 2028 | |
ZamborpimCotrimoxazole | 800 mg/160 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DR-XY18229-B | Oct 15, 2027 | |
ZolbachCotrimoxazole | 800 mg/160 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | Rx | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-5388 | Aug 28, 2029 | |
ZolmedCotrimoxazole | 200 mg/40 mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Inc. | DR-XY17276 | Jun 28, 2031 | |
Zolmed ForteCotrimoxazole | 400 mg/80 mg per 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY27814 | Sep 4, 2027 | |
Zolmed ForteCotrimoxazole | 800 mg/160 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY18795 | Jun 20, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Embryofetal Toxicity Some epidemiologic studies suggest that exposure to BACTRIM during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If BACTRIM is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus (see PRECAUTIONS).
Hypersensitivity and Other Serious or Fatal Reactions Fatalities and serious adverse reactions including severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute febrile neutrophilic dermatosis (AFND), acute generalized erythematous pustulosis (AGEP); fulminant hepatic necrosis; agranulocytosis, aplastic anemia and other blood dyscrasias; acute and delayed lung injury; anaphylaxis and circulatory shock have occurred with the administration of sulfamethoxazole and trimethoprim products, including BACTRIM (see ADVERSE REACTIONS). Hypersensitivity Reactions of the Respiratory Tract Cough, shortness of breath and pulmonary infiltrates potentially representing hypersensitivity reactions of the respiratory tract have been reported in association with sulfamethoxazole and trimethoprim treatment.
Respiratory Failure Other severe pulmonary adverse reactions occurring within days to week of BACTRIM initiation and resulting in prolonged respiratory failure requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO), lung transplantation or death have also been reported in patients and otherwise healthy individuals treated with sulfamethoxazole and trimethoprim products. Circulatory Shock Circulatory shock with fever, severe hypotension, and confusion requiring intravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge with sulfamethoxazole and trimethoprim products, including BACTRIM, in patients with history of recent (days to weeks) exposure to sulfamethoxazole and trimethoprim.
Management of Hypersensitivity Reactions BACTRIM should be discontinued at the first appearance of skin rash or any sign of a serious adverse reaction. A skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AFND, AGEP, hepatic necrosis, or serious blood disorders (see PRECAUTIONS and ADVERSE REACTIONS).
Clinical signs, such as rash, pharyngitis, fever, arthralgia, cough, chest pain, dyspnea, pallor, purpura or jaundice may be early indications of serious reactions. Hemophagocytic Lymphohistiocytosis Cases of hemophagocytic lymphohistiocytosis (HLH) have been reported in patients treated with sulfamethoxazole-trimethoprim.
HLH is a life-threatening syndrome of pathologic immune activation characterized by clinical signs and symptoms of extreme systemic inflammation. Signs and symptoms of HLH may include fever, hepatosplenomegaly, rash, lymphadenopathy, neurologic symptoms, cytopenias, high serum ferritin, hypertriglyceridemia, and liver enzyme and coagulation abnormalities.
If HLH is suspected, discontinue BACTRIM immediately and institute appropriate management. Streptococcal Infections and Rheumatic Fever The sulfonamides should not be used for treatment of group A β-hemolytic streptococcal infections. In an established infection, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as rheumatic fever.
Thrombocytopenia BACTRIM-induced thrombocytopenia may be an immune-mediated disorder. Severe cases of thrombocytopenia that are fatal or life threatening have been reported. Thrombocytopenia usually resolves within a week upon discontinuation of BACTRIM. Clostridioides difficile Associated Diarrhea Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including BACTRIM, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Risk Associated with Concurrent Use of Leucovorin for Pneumocystis jirovecii Pneumonia Treatment failure and excess mortality were observed when BACTRIM was used concomitantly with leucovorin for the treatment of HIV positive patients with P. jirovecii pneumonia in a randomized placebo-controlled trial. 4 Avoid coadministration of BACTRIM and leucovorin during treatment of P. jirovecii pneumonia.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| ACE inhibitors, ARBs, spironolactone and other potassium-raising drugs | Adjust or monitor | Hyperkalemia (label). | Avoid or monitor potassium closely. |
| Dofetilide | Avoid | Higher dofetilide levels; QT prolongation (label). | Contraindicated. |
| Methotrexate | Avoid | Higher free methotrexate; bone marrow suppression (label). | Avoid concurrent use. |
| Cyclosporine | Avoid | Nephrotoxicity (label). | Avoid concurrent use; monitor creatinine if needed. |
| Warfarin, phenytoin, sulfonylureas, digoxin | Adjust or monitor | Higher effect or levels (label). | Monitor INR, levels, glucose. |
| Leucovorin in Pneumocystis treatment | Avoid | Treatment failure and excess mortality (label). | Avoid. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions Potential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2. Table 1: Drug Interactions with BACTRIM Drug(s) Recommendation Comments Diuretics Avoid concurrent use In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.
Warfarin Monitor prothrombin time and INR It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.
Phenytoin Monitor serum phenytoin levels BACTRIM may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.
Methotrexate Avoid concurrent use Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations. Cyclosporine Avoid concurrent use There have been reports of marked but reversible nephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients.
Digoxin Monitor serum digoxin levels Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Indomethacin Avoid concurrent use Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. Pyrimethamine Avoid concurrent use Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding 25 mg weekly may develop megaloblastic anemia if BACTRIM is prescribed.
Tricyclic Antidepressants (TCAs) Monitor therapeutic response and adjust dose of TCA accordingly The efficacy of tricyclic antidepressants can decrease when coadministered with BACTRIM. Oral Hypoglycemics Monitor blood glucose more frequently Like other sulfonamide-containing drugs, BACTRIM potentiates the effect of oral hypoglycemic that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin).
Additional monitoring of blood glucose may be warranted. Amantadine Avoid concurrent use In the literature, a single case of toxic delirium has been reported after concomitant intake of BACTRIM and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.
Angiotensin Converting Enzyme Inhibitors Avoid concurrent use In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of BACTRIM and an angiotensin converting enzyme inhibitor. 5,6 Zidovudine Monitor for hematologic toxicity Zidovudine and BACTRIM are known to induce hematological abnormalities. Hence, there is potential for an additive myelotoxicity when coadministered. 7 Dofetilide Concurrent administration is contraindicated Elevated plasma concentrations of dofetilide have been reported following concurrent administration of trimethoprim and dofetilide.
Increased plasma concentrations of dofetilide may cause serious ventricular arrhythmias associated with QT interval prolongation, including torsade de pointes. 8,9 Procainamide Closely monitor for clinical and ECG signs of procainamide toxicity and/or procainamide plasma concentration if available Trimethoprim increases the plasma concentrations of procainamide and its active N-acetyl metabolite (NAPA) when trimethoprim and procainamide are coadministered. The increased procainamide and NAPA plasma concentrations that resulted from the pharmacokinetic interaction with trimethoprim are associated with further prolongation of the QTc interval. 10
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
The formulation of N 4 -hydroxy metabolite is mediated via CYP2C9.
In vitro studies suggest that trimethoprim is a substrate of P-glycoprotein, OCT1 and OCT2, and that sulfamethoxazole is not a substrate of P-glycoprotein.
Drug Interactions Potential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter.
Sulfamethoxazole is an inhibitor of CYP2C9.
Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2.
Warfarin Monitor prothrombin time and INR It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate).
Phenytoin Monitor serum phenytoin levels BACTRIM may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate).
Oral Hypoglycemics Monitor blood glucose more frequently Like other sulfonamide-containing drugs, BACTRIM potentiates the effect of oral hypoglycemic that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin).
Adverse reactions
Common
- Nausea, vomiting, anorexia
- Rash, urticaria
Serious
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS)
- Hyperkalemia; hyponatremia
- Acute kidney injury, interstitial nephritis, crystalluria
- Bone marrow suppression, thrombocytopenia, hemolytic anemia
- Fulminant hepatic necrosis
- Clostridioides difficile diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The following adverse reactions associated with the use of BACTRIM or sulfamethoxazole and trimethoprim were identified in clinical trials, postmarketing or published reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). Fatalities and serious adverse reactions, including severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute febrile neutrophilic dermatosis (AFND), acute generalized erythematous pustulosis (AGEP); fulminant hepatic necrosis; agranulocytosis, aplastic anemia and other blood dyscrasias; acute and delayed lung injury; anaphylaxis and circulatory shock have occurred with the administration of sulfamethoxazole and trimethoprim products, including BACTRIM(see WARNINGS).
Hematologic: Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, methemoglobinemia, eosinophilia, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura. Allergic/ Immune Reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like syndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria, rash, periarteritis nodosa, hemophagocytic lymphohistiocytosis (HLH), systemic lupus erythematosus, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized erythematous pustulosis (AGEP), and acute febrile neutrophilic dermatosis (AFND) (see WARNINGS).
Gastrointestinal: Hepatitis (including cholestatic jaundice and hepatic necrosis), elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia. Genitourinary: Renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal insufficiency, oliguria and anuria, crystalluria and nephrotoxicity in association with cyclosporine.
Metabolic and Nutritional: Hyperkalemia, hyponatremia (see PRECAUTIONS: Electrolyte Abnormalities), metabolic acidosis. Neurologic: Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache. Psychiatric: Hallucinations, depression, apathy, nervousness. Endocrine: The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents.
Cross-sensitivity may exist with these agents. Diuresis and hypoglycemia have occurred. Musculoskeletal: Arthralgia, myalgia, rhabdomyolysis. Respiratory: Cough, shortness of breath and pulmonary infiltrates, acute eosinophilic pneumonia, acute and delayed lung injury, interstitial lung disease, acute respiratory failure (see WARNINGS).
Cardiovascular System: QT prolongation resulting in ventricular tachycardia and torsades de pointes, circulatory shock (see WARNINGS). Miscellaneous: Weakness, fatigue, insomnia.
Monitoring parameters
- Potassium (hyperkalemia), creatinine (a rise may reflect blocked tubular secretion of creatinine as well as injury), complete blood count, urinalysis for crystalluria; fluid intake. Sodium (hyponatremia). Kidney
- Potassium and creatinine
- Complete blood count
- Urinalysis; hydration
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell, 11 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim.
There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter. Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, BACTRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast milk are approximately 2–5% of the recommended daily dose for infants over 2 months of age. Caution should be exercised when BACTRIM is administered to a nursing woman, especially when breastfeeding jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus.
Pharmacokinetics
Key PK parameters
| Time to peak | 1 to 4 hours |
|---|---|
| Half-life | Sulfamethoxazole about 10 hours; trimethoprim 8 to 10 hours |
| Half-life in kidney failure (ESKD) kidney | Both prolonged in severe impairment (label) |
| Protein binding | Sulfamethoxazole about 70%; trimethoprim about 44% |
| Metabolism (CYP, transporters) | Sulfamethoxazole: N4-acetylation; trimethoprim: partly hepatic |
| Renal excretion kidney | Total sulfonamide 84.5% and free trimethoprim 66.8% in urine within 72 hours |
| Dialyzability kidney | Moderate by hemodialysis; not by peritoneal dialysis (label) |
These steady-state levels were achieved after three days of drug administration. 1 Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion.
Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N 4 -acetylated metabolite. 2 When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.
Both sulfamethoxazole and trimethoprim distribute to sputum, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in human milk.
The mean renal clearance of trimethoprim was significantly lower in geriatric subjects compared with young adult subjects (19 mL/h/kg vs. 55 mL/h/kg).
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY BACTRIM is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized in humans to at least 5 metabolites: the N 4 -acetyl-, N 4 -hydroxy-, 5-methylhydroxy-, N 4 -acetyl-5-methylhydroxy- sulfamethoxazole metabolites, and an N-glucuronide conjugate.
The formulation of N 4 -hydroxy metabolite is mediated via CYP2C9. Trimethoprim is metabolized in vitro to 11 different metabolites, of which, five are glutathione adducts and six are oxidative metabolites, including the major metabolites, 1- and 3-oxides and the 3- and 4-hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms.
In vitro studies suggest that trimethoprim is a substrate of P-glycoprotein, OCT1 and OCT2, and that sulfamethoxazole is not a substrate of P-glycoprotein. Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.
Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely impaired renal function exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see DOSAGE AND ADMINISTRATION section).
Detectable amounts of sulfamethoxazole and trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1.72 µg/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4 µg/mL and 68.0 µg/mL, respectively.
These steady-state levels were achieved after three days of drug administration. 1 Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood.
The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of sulfamethoxazole and trimethoprim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N 4 -acetylated metabolite. 2 When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.
Both sulfamethoxazole and trimethoprim distribute to sputum, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in human milk. Pharmacokinetics in Pediatric Patients A simulation conducted with data from a pharmacokinetic study in 153 infants and children demonstrated that mean steady state AUC and maximum plasma concentration of trimethoprim and sulfamethoxazole would be comparable between pediatric patients 2 months to 18 years receiving 8/40 (trimethoprim/ sulfamethoxazole) mg/kg/day divided every 12 hours and adult patients receiving 320/1600 (trimethoprim/ sulfamethoxazole) mg/day.
Pharmacokinetics in Geriatric Patients The pharmacokinetics of sulfamethoxazole 800 mg and trimethoprim 160 mg were studied in 6 geriatric subjects (mean age: 78.6 years) and 6 young healthy subjects (mean age: 29.3 years) using a non-US approved formulation. Pharmacokinetic values for sulfamethoxazole in geriatric subjects were similar to those observed in young adult subjects.
The mean renal clearance of trimethoprim was significantly lower in geriatric subjects compared with young adult subjects (19 mL/h/kg vs. 55 mL/h/kg). However, after normalizing by body weight, the apparent total body clearance of trimethoprim was on average 19% lower in geriatric subjects compared with young adult subjects. 3 Microbiology Mechanism of Action Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA).
Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, sulfamethoxazole and trimethoprim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria. Resistance In vitro studies have shown that bacterial resistance develops more slowly with both sulfamethoxazole and trimethoprim in combination than with either sulfamethoxazole or trimethoprim alone.
Antimicrobial Activity BACTRIM has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive bacteria Streptococcus pneumoniae Aerobic gram-negative bacteria Escherichia coli (including susceptible enterotoxigenic strains implicated in traveler's diarrhea) Klebsiella species Enterobacter species Haemophilus influenzae Morganella morganii Proteus mirabilis Proteus vulgaris Shigella flexneri Shigella sonnei Other Microorganisms Pneumocystis jirovecii Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cotrimoxazole (Sulfamethoxazole + Trimethoprim) 200 mg + 40 mg/5 mL, 70 mL Suspension | ₱15.40–₱23.00Reference ₱15.40 | per unit | DPRI procurement range |
| Cotrimoxazole (Sulfamethoxazole + Trimethoprim) 400 mg + 80 mg Tablet | ₱0.80–₱1.00Reference ₱0.80 | per tablet | DPRI procurement range |
| Cotrimoxazole (Sulfamethoxazole + Trimethoprim) 400 mg + 80 mg/5 mL, 60 mL Suspension | ₱19.75–₱35.20Reference ₱29.99 | per unit | DPRI procurement range |
| Cotrimoxazole (Sulfamethoxazole + Trimethoprim) 800 mg+160 mg Tablet | ₱1.40–₱3.60Reference ₱1.90 | per tablet | DPRI procurement range |
| 200 mg + 40 mg/5 mL suspension in 120 mL | ₱53.25 | per unit | PhilHealth GAMOT fixed fee |
| 200 mg + 40 mg/5 mL suspension in 70 mL | ₱56.00 | per unit | PhilHealth GAMOT fixed fee |
| 400 mg + 80 mg tablet | ₱3.00 | per tablet | PhilHealth GAMOT fixed fee |
| 400 mg + 80 mg/5 mL suspension in 60 mL | ₱139.00 | per unit | PhilHealth GAMOT fixed fee |
| 800 mg + 160 mg tablet | ₱9.50 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Cotrimoxazole (sulfamethoxazole + trimethoprim) |
| PNF listing | Oral: 400 mg sulfamethoxazole + 80 mg trimethoprim tablet/capsuleRestrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PNF listing | Oral: 800 mg sulfamethoxazole + 160 mg trimethoprim tabletRestrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PNF listing | Oral: 200 mg sulfamethoxazole + 40 mg trimethoprim/ 5 mL suspension, 70mL and 120mL |
| PNF listing | Oral: 400 mg sulfamethoxazole + 80 mg trimethoprim per 5 mL suspension, 60 mL |
| PNF listing | Inj.: 400 mg sulfamethoxazole + 80 mg trimethoprim, 5 mL ampul (IV infusion) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Bactrim · Sun Pharmaceutical Industries, Inc [US FDA-approved label, version 18, December 30, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59d0c04-9c66-4d53-a0e1-cb55570deb62
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Sun Pharmaceutical Industries, Inc. (2024). BACTRIM and BACTRIM DS (sulfamethoxazole and trimethoprim) tablets [Prescribing information; US FDA-approved label, NDA017377, set ID f59d0c04-9c66-4d53-a0e1-cb55570deb62, version effective December 30, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59d0c04-9c66-4d53-a0e1-cb55570deb62
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
